From having seen how enrollment progressed with COVID-19, it appears to me that the speed of enrollment is greatly affected by 1) interest from potential participants and 2) interest from doctors in leronlimab.

I expect that enrollment will happen quickly after leronlimab's profile is raised after FDA approvals and continuing successful results from other trials.